IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2024.04.002

Effect of Mammary Adenocarcinoma Supernatant on Hepatic Fibroblast Differentiation

TOTAL VIEWS: 647

Enze Wang, Ning Tao*, Xiangnan Zhang

Institute of Biophysics, Chinese Academy of Science, Beijing, China.

*Corresponding author: Ning Tao

Published: April 30,2024

Abstract

Mammary adenocarcinoma is the most common malignant tumor in women, and the liver is one of the sites with a high incidence of metastasis. This study established a mammary adenocarcinoma-associated fibroblast cell line (ME-iLX-2) that features premetasis niche based on coculture with the supernatant of hepatic stellate cells (LX-2) and mammary adenocarcinoma cells (TS/A). Multiple experiments, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)MTT, Flow Cytometry (FCM), wound-healing, lactic acid, real-time quantitative polymerase chain reaction (qPCR) and WB assays, were carried out to investigate the connection between mammary adenocarcinoma cells and hepatic stellate cells and the source of cancer-associated fibroblasts in the premetastatic microenvironment and to confirm the importance of vascular endothelial growth factor (VEGF) in mammary adenocarcinoma supernatant-induced hepatic fibroblast differentiation. This study determined the following: (1) After long-term coculture with supernatant, LX-2 significantly promoted the proliferation and migration of tumor cells, and massive apoptosis of LX-2 cells occurred; (2) VEGF expression in LX-2 cells was positively correlated with the duration of coculture with supernatant. In addition, with an established linear regression model, high expression of VEGF is suggested to be one of the molecular properties of cancer-associated fibroblasts.

References

[1] Stephen Paget. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Reviews, 1989, 8(2): 98-101.

[2] Hans Schreiber and Donald A. Rowley. Awakening Immunity. Science, 2010, 330(6005): 761-762.

[3] Robert D Leone and Jonathan D Powell. Metabolism of immune cells in cancer. Nature Reviews Cancer, 2020, 20(9): 516-531.

[4] Gavin P Dunn, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002, 3(11): 991-998.

[5] Poad H. The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers (Basel), 2022, 14(21):5391.

[6] Jian-Guo Cao, et al. Vascular Basement Membrane-derived Multifunctional Peptide, a Novel Inhibitor of Angiogenesis and Tumor Growth. Acta Biochimica et Biophysica Sinica, 2006, (07):514-521.

[7] Meng F. Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon caner model. PLoS One, 2022, 17(4):e0264896.

[8] Muller S. Brain Metastases from Colorectal Cancer: A Systematic Review of the. Literature. and Meta-Analysis to Establish a Guideline for Daily Treatment. Cancers (Basel), 2021, 13(4):33669974.

[9] Seong Ah Park, et al. Structure and function of vascular endothelial growth factor and its receptor system. BMB Reports, 2018, 51(2): 73-78.

[10] G H Fong, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 1995, 376(6535): 66-70.

[11] F Shalaby, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 1995, 376(6535): 62-6.

[12] Lena. SMaC-W. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research, 2006, 312(5): 549-560.

[13] Bo Zhang, et al. Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma. Biomedicine & Pharmacotherapy, 2018, 105: 1-9.

[14] Hongjun Zhu and Shuanglin Zhang. Hypoxia inducible factor‐1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia‐induced angiogenesis in lung cancer. Journal of Cellular Biochemistry, 2018, 119(9): 7707-7718.

[15] Napoleone GH-PaF. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Research, 2005, 65(3): 671-80.

[16] Aristidis. P. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. The Journal of Steroid Biochemistry and Molecular Biology, 2008, 108(3-5): 261-6.

[17] P Nanni, et al. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clinical & Experimental Metastasis, 1983, 1(4): 373-380.

How to cite this paper

Effect of Mammary Adenocarcinoma Supernatant on Hepatic Fibroblast Differentiation

How to cite this paper: Enze Wang, Ning Tao, Xiangnan Zhang. (2024) Effect of Mammary Adenocarcinoma Supernatant on Hepatic Fibroblast DifferentiationInternational Journal of Clinical and Experimental Medicine Research8(2), 198-204.

DOI: http://dx.doi.org/10.26855/ijcemr.2024.04.002